Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
3.97B | 3.96B | 4.21B | 3.81B | 3.37B | 3.39B | Gross Profit |
400.46M | 378.53M | 394.55M | 347.23M | 323.30M | 312.71M | EBIT |
197.68M | 167.73M | 195.82M | 113.49M | 116.92M | 100.87M | EBITDA |
253.34M | 236.25M | 288.55M | 243.08M | 240.28M | 216.17M | Net Income Common Stockholders |
142.70M | 111.81M | 139.09M | 138.24M | 138.91M | 117.48M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
265.09M | 345.11M | 256.23M | 274.81M | 270.17M | 385.81M | Total Assets |
3.28B | 3.15B | 3.32B | 3.39B | 2.46B | 2.29B | Total Debt |
480.19M | 279.59M | 469.61M | 495.38M | 291.32M | 371.58M | Net Debt |
215.09M | -65.52M | 213.38M | 220.57M | 21.14M | -14.22M | Total Liabilities |
2.02B | 1.83B | 2.11B | 2.30B | 1.43B | 1.31B | Stockholders Equity |
1.26B | 1.32B | 1.21B | 1.10B | 1.03B | 977.48M |
Cash Flow | Free Cash Flow | ||||
335.18M | 341.32M | 61.77M | -127.85M | 85.48M | 160.28M | Operating Cash Flow |
405.37M | 436.50M | 165.82M | -26.24M | 142.58M | 210.37M | Investing Cash Flow |
-70.25M | -94.95M | -93.30M | -101.56M | -56.97M | -49.85M | Financing Cash Flow |
-282.72M | -255.59M | -92.72M | 139.29M | -203.88M | -1.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $4.52B | 19.54 | 11.03% | ― | -1.50% | 1.84% | |
76 Outperform | $3.51B | 25.19 | 10.93% | ― | -0.69% | 42.26% | |
75 Outperform | $3.82B | 27.67 | 16.73% | ― | 14.93% | 12.89% | |
73 Outperform | $2.91B | 38.18 | 5.02% | ― | 11.65% | ― | |
70 Outperform | $5.08B | 47.64 | 4.39% | 1.32% | -3.43% | -50.48% | |
68 Neutral | $1.29B | 24.76 | 4.84% | 1.86% | -7.36% | -20.46% | |
61 Neutral | $11.29B | 10.07 | -7.05% | 2.96% | 7.47% | -10.75% |
On May 14, 2025, Plexus Corp.’s Board of Directors approved a new share repurchase program, authorizing the buyback of up to $100 million of its common stock. This will commence after the current $50 million program, which has a remaining balance of $17.9 million as of May 13, 2025, expires. The company has not set a specific schedule for repurchases, indicating flexibility in timing and amount based on market conditions and other factors.
The most recent analyst rating on (PLXS) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Plexus stock, see the PLXS Stock Forecast page.